Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Implantica

60.20 SEK+1.01 %28.8, 9.27
Less than 1K followers

IMP A SDB

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
+1.01 %
+2.21 %
-3.99 %
+30.87 %
+20.16 %
-15.69 %
+144.22 %
-45.27 %
-37.66 %

Implantica operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes implantable medical instruments, which are also used for the treatment of diseases affecting the esophagus. In addition to the main business, related ancillary services are offered, particularly focused on eHealth. The business is operated globally with the largest presence in North America and Europe.

Read more
Market cap
71.23B SEK
Turnover
320.55K SEK
Revenue
22.39M
EBIT %
-990.01 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
ShowingAll content types

Forum discussions
Today, RefluxStop has finally received FDA approval, and the company can officially begin its launch in the U.S. market. With this approval, one of the biggest risk factors for this investment has been removed. Today is also the company’s Q2 earnings release, so it will be very interesting...
8/21/2026, 6:01 AM
by Pevitaha
4
Implantica’s RefluxStop® sparked great enthusiasm at the American Foregut Society meeting in the United States ahead of the expected FDA approval. Medtech company Implantica presented its RefluxStop® implant, developed for the treatment of acid reflux, at the AFS annual meeting in...
9/17/2025, 6:49 AM
by Pevitaha
4
Vahva on luotto firmalla, että FDA hyväksyntä tulee, kun on kehitetty uusi tuotantolaite jolla saadaan nopeammin valmistettua RefluxStopia. Implantica finishes new multi-cavity production tool for RefluxStop® to support manufacturing ramp-up in the U.S. pending FDA approval logo ...
8/13/2025, 6:59 AM
by Pevitaha
3
Based on Q2, Implantica’s European business is moving in the right direction, coinciding with the FDA approval that has opened up the U.S. market. Q2 revenue grew by 66% to €0.717M, and H1 revenue by 34% to €1.574M. The starting level is still low, but the growth rate is promising...
8/21/2026, 6:48 AM
by Pevitaha
2
implantica.com Implantica submits final response to FDA in the PMA application for... Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop® device for the treatment of acid reflux, a treatment...
5/20/2026, 10:03 AM
by Pevitaha
2
Implanticas Q3’25 webcast: Inderes Implantica, Webcast, Q3'25 - Inderes Time: 2025-10-31 15:00 Language: en Language: en Sector: Health care - Pharmaceuticals & Biotechnology Activity: Audiocast with teleconference
11/4/2025, 12:40 PM
by Isa Hudd
2
Toinen julkaisu RefluxStopin viiden vuoden seurannan tuloksista. Eihän tässä voi kuin odotella FDA hyväksynnän tuloksia, jotka toivottavasti tulee tässä lähiaikoina (autumn). implantica.com Implantica announces second publication of groundbreaking 5-year results from... Implantica...
8/7/2025, 7:00 AM
by Pevitaha
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
19.11
2026

Interim report Q3'26

Press release25.08.2026, 08.00

Implantica to host Capital Markets Day in Stockholm on September 9

Implantica
Implantica, Audiocast, Q2'26
Webcast21.08.2026, 15.00

Implantica, Audiocast, Q2'26

Implantica
Regulatory press release21.08.2026, 08.00

Implantica publishes Interim Report January - June 2026 (Q2)

Implantica

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release20.08.2026, 23.05

Implantica receives FDA approval for RefluxStop® - Opening the U.S. market

Implantica
Press release14.08.2026, 10.00

Implantica presents the second quarter (Q2 2026) on August 21 at 15:00 CEST

Implantica
Regulatory press release10.06.2026, 19.50

Bulletin from the Annual General Meeting of Implantica AG

Implantica
Press release09.06.2026, 08.00

Implantica announces launch of 20[th] RefluxStop® Center of Excellence in Spain, part of a world-renowned US hospital group

Implantica
Regulatory press release22.05.2026, 08.00

Implantica publishes Interim Report January - March 2026 (Q1)

Implantica
Regulatory press release21.05.2026, 11.00

Notice of Annual General Meeting of Implantica AG

Implantica
Press release21.05.2026, 08.00

Implantica announces publication of a new health economics study showing RefluxStop®'s superior cost-effectiveness in the treatment of GERD in the Italian Healthcare System

Implantica
Press release20.05.2026, 08.00

Implantica submits final response to FDA in the PMA application for RefluxStop® for U.S. market approval

Implantica
Press release19.05.2026, 08.01

Implantica announces new breakthrough long-term RefluxStop® data on severe sufferers presented at DDW 2026

Implantica
Press release19.05.2026, 08.00

Implantica: RefluxStop® gains momentum at DDW 2026

Implantica
Press release18.05.2026, 09.00

Implantica presents the first quarter (Q1 2026) on May 22 at 15:00 CET

Implantica
Regulatory press release06.05.2026, 08.00

Implantica publishes Annual Report 2025

Implantica
Press release21.04.2026, 08.00

Implantica announces landmark RefluxStop[® ]study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature's Scientific Reports

Implantica
Regulatory press release25.02.2026, 08.00

Implantica publishes Year-end Report, January - December 2025 (Q4)

Implantica
Press release18.02.2026, 12.45

Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET

Implantica
Press release27.01.2026, 08.00

Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop®

Implantica
Press release10.12.2025, 08.00

Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop®

Implantica